Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Neuron23
681 Gateway Blvd.3rd Floor
South San Francisco, CA 94080
https://neuron23.com/

Neuron23 Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA, and Munich, Germany.

Key Contact
Name
Nancy Stagliano
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
12/16/20 $113,500,000 Series A and B Acorn Bioventures
Cowen Healthcare Investments
HBM Partners
Kleiner Perkins Caufield and Byers
Perceptive Advisors
Redmile Group
Surveyor Capital
Westlake Village BioPartners


Featured Reading